Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|European Journal of Cancer|2020Cited by 71
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|medRxiv|2020Cited by 6
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Journal of Clinical Medicine|2025Cited by 4
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Luigia Stefania Stucci et al.|Cancers|2025Cited by 3
354P Sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer patients: A multicenter real-world updated analysisR. Caputo, Michelino De Laurentiis, Giuseppina Rosaria Rita Ricciardi et al.|ESMO Open|2025Cited by 1